Is NMN Banned in the UK? MHRA and FSA Status Explained (2026)

Short answer, up front. NMN is not banned in the United Kingdom as of September 2026. The Food Standards Agency classes it as a novel food and there is an active application under regulatory assessment, but products already on the market remain legal to buy and sell while that review continues.

The question keeps coming up because the United States took a different route. In October 2022 the US Food and Drug Administration ruled that NMN could not be sold as a dietary supplement, and that decision has echoed through Reddit threads, YouTube videos and forum posts ever since. UK buyers see the American news and reasonably ask whether the same applies here.

This guide sets out what the FSA and the Medicines and Healthcare products Regulatory Agency have actually said, why UK sellers cannot legally make health claims about NMN even though the product is legal, what the human safety trials suggest about continued use, and how to pick a brand that is clearly operating within the current UK rules.

Top pickMade in the UK · GMP certified

NMN 500mg Delayed Release Capsules

60 vegan capsules · 2-month supply at 1/day

• 500mg beta-nicotinamide mononucleotide per capsule
• Delayed release capsule, dissolves lower in the digestive tract
• Sold on a novel food transitional basis, no health claim made

£24.95 £0.42 per day

Add to Cart

Vegan · 30-day returns · Free UK shipping

The short answer: NMN is not banned in the UK

Search "is NMN banned in the UK" and you will find blog posts, Reddit threads and YouTube titles that all say slightly different things. Some are confidently wrong, some are cautious, and a few are technically right but read as if the product is illegal. The plain truth is that NMN is currently legal to purchase and sell in Great Britain, and it is not on any MHRA prohibited list.

What NMN is subject to is a status called novel food classification. That means the FSA has decided NMN was not consumed to a significant degree in the UK or European Union before 15 May 1997 and therefore needs authorisation before it can be freely marketed as a food supplement. Applications for authorisation are actively being assessed.

Being under assessment is not the same as being banned. Products that were on the market before certain transitional dates can continue to be sold whilst the FSA reviews the science, provided they comply with general food safety and labelling rules. That is why you can still buy NMN from UK retailers today.

What the FSA actually says

The Food Standards Agency is the UK's official food regulator. Since Brexit, novel foods in Great Britain fall under assimilated Regulation (EU) 2015/2283, which was retained into UK law and is administered by the FSA. The Regulations were transposed domestically by the Novel Foods (England) Regulations 2018.

Under those rules, a novel food is any food or ingredient not consumed to a significant degree by humans in the UK or EU before 15 May 1997. Beta-nicotinamide mononucleotide, isolated at scale for supplement use, meets that definition. Isolated NMN was not a routine part of the pre-1997 diet even though small trace amounts appear in some foods.

An application for the approval of beta-nicotinamide mononucleotide is listed on the FSA's public Register of Regulated Product Applications. The novel food process is a technical review of safety, dose ranges and labelling, not a ban. The register is updated by the FSA as applications progress.

Why so many people think NMN is banned

The confusion almost always comes from the United States. In October 2022 the US Food and Drug Administration issued a decision that NMN could no longer be marketed as a dietary supplement under the Federal Food, Drug and Cosmetic Act. The reason was procedural rather than a safety concern.

A US pharmaceutical company had begun clinical trials of NMN as an investigational drug before it was widely sold as a supplement. Under a US rule known as the drug exclusion clause, once an ingredient enters the drug approval pipeline in that sequence, it cannot then be reclassified as a food supplement. The 2022 letter reversed an earlier FDA position that had allowed NMN as a supplement.

That ruling is US-specific. The UK and EU have their own regulatory processes and are working through novel food authorisation instead of a drug exclusion analysis. The FDA decision does not carry across the Atlantic, though the news cycle around it has convinced many UK buyers that the same rules apply here.

What UK sellers cannot legally claim about NMN

Here is the part every honest UK seller has to be careful about. No health claim for NMN has been authorised on the Great Britain Nutrition and Health Claims Register. That register is maintained by the Department of Health and Social Care and lists every health claim a food or supplement may legally make in the UK.

Because NMN carries no authorised claim, sellers cannot legally state that it boosts energy, raises NAD+, reverses ageing, extends healthspan, protects DNA, improves fertility, treats or prevents any disease, or any similar wording. Doing so is a breach of the Nutrition and Health Claims (England) Regulations 2007. That is enforceable regardless of the underlying science.

If you see a UK product page, an influencer post or a paid ad making one of those claims, you are looking at a regulatory breach. It does not automatically mean the product itself is unsafe, but it does mean the seller is not compliant. Trust the sellers who describe NMN in neutral, non-medicinal language and let the science speak for itself in the reference sections.

Is NMN safe to keep taking during the FSA review?

Nothing about the FSA novel food process is a safety recall. Novel food authorisation is an administrative categorisation, and the FSA has not issued any advice telling UK consumers to stop taking NMN. The published human safety data on isolated NMN, though not extensive, is generally reassuring at typical supplement doses.

A 2022 randomised placebo-controlled trial from Japan gave healthy adults 1,250mg of NMN daily for four weeks and recorded no serious adverse events, with blood NAD+ metabolites rising as expected (Fukamizu et al., 2022, DOI 10.1038/s41598-022-18272-y). A 2021 trial published in Science gave prediabetic women 250mg for ten weeks with a similar safety profile (Yoshino et al., 2021, DOI 10.1126/science.abe9985). An earlier tolerability trial dosed 100, 250 and 500mg in Japanese men without safety concerns (Irie et al., 2020, DOI 10.1507/endocrj.EJ19-0313).

These are trial-level datasets, not health claims. What they tell us is that NMN at supplement-relevant doses has been repeatedly tested in humans without serious adverse events being reported. As with any supplement, speak to your GP before starting NMN if you are pregnant, breastfeeding, immunocompromised, taking any prescribed medication, or under 18.

What could change when the FSA finishes

The novel food process can end in one of three ways, and it is worth understanding all of them because you will see each outcome speculated about online. None of them is a snap decision, and the FSA typically publishes a draft assessment for comment before finalising anything.

Full authorisation with conditions. The FSA grants a market-wide authorisation, usually specifying maximum daily dose, permitted target population, mandatory labelling text and any subgroups to warn, and most novel food outcomes to date have landed here. UK sellers keep selling within the specified conditions.

Applicant-specific authorisation. Under the UK novel food framework, an applicant that has submitted its own dossier can receive a five-year period of protection during which only they may market the ingredient. Other sellers would then need their own authorisation to continue.

Rejection. The FSA can decline the application if the safety dossier is judged inadequate. NMN would then need to leave UK shelves. On the published human trial evidence, most industry commentators regard this outcome as less likely than either of the first two, but it is a real possibility and honest sellers should say so.

How to choose an NMN brand while regulation settles

If you are going to keep taking NMN through the FSA review, use the transitional period as a chance to raise your standards. Choose a brand that reads as clearly compliant rather than one leaning on aggressive claims. It is a decent proxy for how they will behave once the rules tighten.

The checklist below is what a good NMN product page should let you verify. If you cannot answer yes to at least the first three questions, consider a different supplier. A brand cutting corners on labelling now is unlikely to be trustworthy on batch purity either.

If you want to go deeper on the buying decision itself, our Best NMN Supplement UK guide ranks the current UK options against these criteria and picks a top overall, a value pick and a stack option. Our NMN dosage and benefits guide covers the trial evidence on dose, and the NMN side effects guide collects the tolerability data from the same trials cited above.

How we think about our own compliance

Because the FSA process is ongoing, we try to be direct about how Supplements Wise operates. Our NMN products are UK made in a GMP-certified facility, are sold on a transitional novel food basis under FSA guidance, and our product pages deliberately avoid any health claim. We describe what the capsule contains and how the trials dosed it, not what it will do for you.

We also monitor the FSA Register of Regulated Product Applications for updates and will adapt labelling, dose or availability if the eventual authorisation requires it. If the FSA finalises specific conditions, our product pages will reflect them straight away. If a rejection is issued, we will withdraw stock rather than resell it, and we would refund pre-orders held at that point.

We stock two NMN options at present. NMN 500mg is the plain single-ingredient capsule for people who want to control their own stack, and the NMN Complex combines NMN with trans-resveratrol, quercetin and supporting cofactors for people who prefer a one-capsule daily. Both are delayed release, and neither carries a health claim.

Comparison shoppers may want the wider longevity picture too. Our Sinclair Longevity Stack guide covers the wider protocol, our Best Time to Take NMN guide covers timing, and our NMN timeline guide maps the trial evidence to a week-by-week expectation. All three assume the compliance context this article has set out.

Frequently asked questions